CMS released the proposed Outpatient Prospective Payment System – OPPS rule for 2018— which includes a major proposed cut for separately payable drugs purchased under the 340B program. The proposal would reduce reimbursement for separately payable Medicare Part B drugs purchased at 340B prices. Reimbursement would drop from average sales price plus 6% to ASP […]
How 340B payment cuts are affecting the oncology practice?









